Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel chemoradiotherapy for elderly stage IB-III esophageal cancer
jRCTs031180283Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in esophageal cancer, sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Dose-limiting toxicity frequency and Two-year survival rate. Started Apr 2016; status: active, not recruiting.
02
Drugs
paclitaxel
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCTs031180283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180283.